18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy (IMMUNOPET)
18FluoroDeoxyGlucose-Positron Emission Tomography (PET) in Patients With Melanoma or Non Small Cell Lung Cancer Treated With Immunotherapy
調査の概要
詳細な説明
Study EFS in patients with melanoma or NSCLC treated by immunotherapy (anti CTLA4 or anti PDL1) and performed18FDG PET
Multicentric retrospective study
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Brest、フランス、29609
- CHRU de Brest
-
Landerneau、フランス
- CH de Landerneau
-
Morlaix、フランス
- Centre Hospitalier de Morlaix
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- patients treated for melanoma or NSCLC with immunotherapy (anti CTLA4 or antiPDL1)
- patients treated in Brest, Morlaix, Landerneau hospital
- patients performed FDG PET
- no opposition to study
Exclusion Criteria:
- age under 18 years old
- refusal to participate
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
measure of progression free survival (obtained by the delay between the date of initiation of immunotherapy until the date of first documented progression disease in patients with melanoma or NSCLC treated by immunotherapy
時間枠:up to 50 months
|
From date of initiation of treatment until the date of first documented progression disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria. |
up to 50 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
measure of overall survival (obtained by the delay between the date of initiation of immunotherapy until the date of death related to disease in patients with melanoma or NSCLC treated by immunotherapy
時間枠:up to 50 months
|
From date of initiation of treatment until the date of death related to disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria. |
up to 50 months
|
|
Study different criteria (RECIST, iRECIST, PERCIST and PECRIT) to predict PFS or OS
時間枠:up to 50 months
|
Interpretation according to 4 criteria to predict response to immunotherapy
|
up to 50 months
|
|
study the potential correlation between PET data and clinicobiological data
時間枠:up to 50 months
|
correlation between adverse events (AE) due to immunotherapy described on PET data and AE detected on clinicobiological data
|
up to 50 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。